Friday, May 22, 2015

FDA Approves New Three-Month Long-Acting Antipsychotic Invega Trinza


The FDA has approved Invega Trinza (paliperidone palmitate), a long-acting atypical antipsychotic intended to treat schizophrenia, from Janssen Pharmaceuticals Inc.

The approval of the injectable antipsychotic, which remains active in the body for three months, was based on results from a two-year maintenance trial with 506 patients diagnosed with schizophrenia. The analysis, published March 29 in JAMA Psychiatry, showed that patients who were administered Invega Trinza were statistically less likely to relapse than those who were administered placebo. The most common adverse effects of the medication included injection-site reactions, weight gain, upper respiratory tract infections, and extrapyramidal symptoms.

The newly approved antipsychotic will come with a boxed warning stating that it is not approved for patients with dementia-related psychosis and that use of the drug may increase the risk for death in elderly patients with dementia.

Before patients can begin taking Invega Trinza, they must first show tolerability to Janssen's Invega Sustenna, a one-month form of paliperidone palmitate, for at least four months.

Invega Trinza was approved under the FDA's priority review process, a fast track for drugs thought to represent a significant advance in medical care. It is being marketed by Janssen.

For more information about psychotropic medications in the pipeline, see the Psychiatric News article "Candidates, Innovation Missing From Psychotropic Drug Pipeline."

Thursday, May 21, 2015

Experts Discuss Mental llness, Risk for Violence, and Gun Ownership


An evidence-based assessment of dangerousness—not mental illness, per se—should guide public policies regarding restrictions on gun ownership, Jeffrey Swanson, Ph.D. (left), of Duke University School of Medicine said during the "Do Firearm Restrictions Prevent Suicide and Violence in People With Serious Mental Illness?" workshop at the APA annual meeting in Toronto. He was joined by Joshua Horwitz, executive director of the Educational Fund to Stop Gun Violence.

Swanson, a professor of psychiatry and behavioral science, presented evidence showing that while there are instances when those with a serious mental illness are at increased risk of violence, serious mental illness, on its own, contributes very little to overall violence towards others. (Mental illness alone carries a far greater risk for suicide.)

For instance, he showed data from a survey of public behavioral health system psychiatric outpatients with serious mental illness in five U.S. sites demonstrating that the risk of violence rose significantly when in combination with substance abuse, early victimization, and/or exposure to violence in one's current social environment.

Swanson offered these following principles to guide public policy regarding restricting access to firearms:

  • Prioritize contemporaneous risk assessment based on evidence of behaviors that correlate with violence and self-harm at specific times, not mental illness or treatment history per se as a category of exclusion;

  • Preempt existing gun access, rather than simply thwarting a new gun purchase by a dangerous person;

  • Provide legal due process for deprivation of gun rights;

  • Preserve confidential therapeutic relationships;

  • Prevent the unpredictable through universal background checks, but also by reducing the social determinants of violence and investing in improved access to mental health and substance abuse services.

For more information on gun policy and mental illness, see the Psychiatric News article "Capitol Hill Gets Straight Story On Gun Violence, Mental Illness" and the Psychiatric Services article "Gun Policy and Serious Mental Illness: Priorities for Future Research and Policy."

(Image: Mark Moran)

Wednesday, May 20, 2015

Understanding the Motivations of Cheating Athletes Can Guide Treatment


“Deflategate” may be the word of the day in the sports world, but it is neither the first nor the last example of athletes cheating to gain an edge on competitors. Winning is everything to many athletes, no matter the cost to their integrity and health.

Cheating in sports likely falls into one of the four B’s: Betting, Bribery, Battery, and Banned substances, said Thomas Newmark, M.D., a professor of psychiatry at the Rowan School of Medicine, at APA’s 2015 annual meeting in Toronto today. He gave an overview of infamous sports scandals in cheating, ranging from cyclist Lance Armstrong’s use of performance enhancement drugs to the ice skater Tanya Harding’s planned assault on fellow competitor Nancy Kerrigan at the Olympic trials in 1991. Newmark discussed that underlying motives behind some cheating scenarios are the gaining of fame, extreme financial incentives, success, and acceptance, or, in the case of collegiate athletes, grades and maintaining eligibility.

Psychiatrists can step in and help athletes caught cheating by educating them about the error of their ways or helping them cope with the stress of dealing with a suspension or the end of a career, said Eric Morse, M.D., a sports psychiatrist who works with professional, college, and youth athletes and teams. Ironically, sometimes it is the psychiatrist who is pressured to cheat—to provide a medical diagnosis that helps a college athlete drop a course he is failing or “legalize” a banned medication with a back-dated prescription.

Dan Begel, M.D., a cofounder of the International Society for Sport Psychiatry, discussed that athletes with personality disorders such as narcissistic, borderline, or antisocial personalities are at higher risk of cheating behaviors. “Understanding the deeper motivations of such athletes can drive treatment,” said Begel. “It is important to explore childhood and family and cultural dynamics to develop a treatment plan.”

Therapy tools highlighted during the session to treat athletes included cognitive-behavioral therapy, family therapy, dynamic therapy, and supporting therapy. The experts emphasized that the key role of psychiatrists in sports medicine is to educate athletes about cheating, help them not to cheat again, and help with the consequential stress of being caught—which could result in a loss of identity for the player.

Ira Glick, M.D., professor emeritus of psychiatry and behavioral sciences at the Stanford University School of Medicine, said that a personal, family, and cultural history of the athlete are good starting points for therapy.

“Cognitive-behavioral therapy, family therapy, dynamic therapy, or supportive therapy can help,” said Glick. “Often the elite athlete may feel a sense of entitlement that needs to be addressed.”

For more on how sports can inform therapy, see Psychiatric News article “Why Sports Evoke Passion, for Better or Worse.”

(Image: Peter Weber/Shutterstock.com)

Tuesday, May 19, 2015

NIDA Director Calls for Humane Response to Addiction as a Brain Disorder


“If we as psychiatrists can embrace addiction as a disease of the brain that disrupts the systems that allow people to exert self-control, we can reduce the stigma that surrounds this disorder—for insurance companies and the wider public—and help to eliminate the shame and suffering that accompany the addict who experiences relapse after relapse after relapse.”

That was the message that Nora Volkow, M.D., (left) director of the National Institute on Drug Abuse, brought to APA members at the 59th Convocation of Distinguished Fellows at APA’s 2015 annual meeting in Toronto Monday evening.

Volkow opened her speech with a moving and emotional story of how she learned of her grandfather’s lifetime of chronic alcoholism and suicide; he had died when she was a girl of 6 in Mexico, but Volkow’s mother did not reveal the truth of her grandfather’s addiction and death until many years later, when her mother was dying and after Volkow had already achieved distinction as an addiction expert.

It was a dramatic illustration of the despair experienced by people who have an addiction and continue to engage in a behavior that they may know is destroying them—a phenomenon that Volkow has devoted her career to understanding. She gave a brief overview of her own research and the evolution of addiction science, describing how it was once believed that addiction was a disorder of hyperactive reward centers in the brain—that addicts sought out drugs or alcohol because they were especially sensitive to the pleasure-inducing effects of dopamine.

But Volkow explained that in recent years research has revealed just the opposite: that addicts are actually less sensitive to the effects of dopamine. They seek out drugs because of the very potency with which they can increase dopamine in the brain, often at the expense of other pleasurable natural stimulants that do not increase dopamine so dramatically. And it is the neurobiological reflection of the phenomenon of “diminishing effects” that addicts typically report clinically: they require more and more of the drug to get a similar effect.

"This was completely counterintuitive," Volkow said.

Moreover, she emphasized that addiction to drugs disrupts multiple systems in the brain—not simply reward centers—that govern the ability to plan, anticipate, and change behavior in response to changing circumstances. Volkow said it is this phenomenon that accounts for the “craving” experienced by addicts and alcoholics in response to environmental triggers—often leading to what she characterized in the account of her grandfather’s death as that “one last moment of self-hatred.”

(Image: David Hathcox)

Monday, May 18, 2015

ABMS Executive Defends Importance of MOC Part 4 in Assembly Address


"I absolutely believe we should keep the performance-in-practice component of Maintenance of Certification (MOC)," said American Board of Medical Specialties (ABMS) President and Chief Executive Lois Margaret Nora, M.D., J.D., during a special address to the APA Assembly Sunday morning at APA’s 2015 annual meeting in Toronto. However, Nora did note that the MOC process itself and the Part 4 performance-in-practice component (also referred to as "Improvement in Medical Practice") needs to be improved and refined.

According to Nora, the ABMS plans to respond to physician concerns over Part 4 by a "relaxation" of requirements and an expansion of activities that count toward fulfilment of performance in practice. "With the appropriate flexibility, I believe that performance in practice will be embraced by physicians," Nora said. ("Performance in practice" refers to a requirement that physicians build into their routine practice the capacity to assess their performance continually against guidelines for best practices and make improvements to meet those guidelines.)

Up to now it has been a chilly embrace. In an interview with Psychiatric News last year, Larry Faulkner, M.D., president of the American Board of Psychiatry and Neurology (ABPN), explained that the "the performance-in-practice issue is a controversial and difficult one. … It boils down to a quality-improvement process. In general, physicians are going to have to demonstrate that they have looked at their practices and identified issues that need to be improved."

But Part 4 has been the object of widespread physician concern and even anger. At the March meeting of the APA Board of Trustees, the Board voted to write a letter to Faulkner requesting that ABPN advocate to the ABMS that Part 4 be eliminated. (ABPN operates under criteria established by the ABMS).

The letter was the result of a motion, spurred by the Assembly Executive Committee and made at the Board of Trustees meeting in March, reflecting concerns over the limited evidence base for Part 4. Also at its March meeting, the Board established a joint Board-Assembly work group to evaluate the broad issue of MOC in psychiatry and its relationship to maintenance of state licensure and requirements of other accrediting bodies.

Note: Just prior to the start of APA's annual meeting, the ABPN announced that the feedback module in Part 4 will become optional as of January 1, 2016. The Part 4 Clinical Module component (chart review) will remain a requirement, and additional approved activities are now available on ABPN’s website. This change is in compliance with current MOC standards as mandated by the ABMS.

For more on APA’s efforts to eliminate Part 4 of MOC program, see the Psychiatric News article “APA Urges ABPN to Advocate for Elimination of MOC Part 4.”

(Image: David Hathcox)

Friday, May 15, 2015

Study Finds Long-Term Depression Increases Risk for Stroke in Older Adults


Persistent symptoms of depression in adults ages 50 and older may double their risk for stroke, according to a recent study published in the Journal of the American Heart Association.

Researchers from Harvard T.H. Chan School of Public Health analyzed medical records of more than 16,000 older adults who participated in the Health and Retirement Study between 1998 and 2010. As part of the study, participants were interviewed every two years about their depressive symptoms, history of stroke, and stroke risks factors.

Nearly 2,000 strokes among the participants were reported over the course of the study. The researchers found that individuals who displayed high levels of depressive symptoms during two consecutive interviews (over a four-year period) were more than twice as likely to experience a stroke during the subsequent two years compared with participants who had low depressive symptoms during two consecutive interviews. Even people who had depressive symptoms at the first interview but not the second had a 66 percent higher stroke risk, the study reports.

The researchers hypothesized that depression may influence stroke risk through physiological changes involving the accumulation of vascular damage over time.

“This is the first study evaluating how changes in depressive symptoms predict changes in stroke risk," lead author Paola Gilsanz, Sc.D, a postdoctoral research fellow at Harvard, said in a press release. “If replicated, these findings suggest that clinicians should seek to identify and treat depressive symptoms as close to onset as possible, before harmful effects on stroke risk start to accumulate.”

To read more about the relationship between depression and stroke, see the Psychiatric News article "Collaborative Care for Depression Can Reduce Risk for Heart Attacks, Strokes."

(Rocketclips, Inc./shutterstock.com)

Thursday, May 14, 2015

Treating Depressed Mothers With Escitalopram May Have Greater Benefit to Children, Study Finds


School-age children of mothers with major depression consistently have elevated rates of depression. Now a study in the May American Journal of Psychiatry finds that the children of depressed mothers who took escitalopram for 12 weeks showed significant improvements in depressive symptoms and functioning compared with those whose mothers took bupropion or a combination of the two drugs.

For the study, Myrna Weissman, Ph.D., of Columbia University and colleagues independently assessed 135 children (ages 7-17) and 76 depressed mothers participating in a 12-week double-blind randomized clinical trial testing the effects of escitalopram (10 mg to 40 mg daily), bupropion (150 mg to 450 mg daily), or a combination of the two.

While depressed mothers receiving escitalopram monotherapy, bupropion monotherapy, or combination treatment had a high remission rate overall (67%) and a significant reduction in symptoms over 12 weeks, only in the escitalopram group was significant improvement of the mothers' depression associated with improvement in the child’s symptoms.

The researchers suggest this difference may be due to changes in parental functioning. "Mothers in the escitalopram group reported significantly greater improvement, compared with the other groups, in their ability to listen and talk to their children, who as a group reported that their mothers were more caring over the 12 weeks," they wrote.

“This study highlights the complexity of interpreting the benefit of mothers’ medication treatment alone on children’s short-term outcomes,” Mary Jo Coiro, Ph.D., an assistant professor of psychology at Loyola University Maryland, wrote in an accompanying Perspectives piece in the journal. “Ultimately, a public health perspective that incorporates screening, prevention, and treatment of both parents and children is likely to be most effective in reducing the burden of parental depression. Interventions must offer a range of services and be flexible enough to identify which families require parenting support, medication, psychotherapy, home- or school-based services, and social services."

(Image: Irina Bg/shutterstock.com)

Disclaimer

The content of Psychiatric News does not necessarily reflect the views of APA or the editors. Unless so stated, neither Psychiatric News nor APA guarantees, warrants, or endorses information or advertising in this newspaper. Clinical opinions are not peer reviewed and thus should be independently verified.